Jaguar Health Statistics
Total Valuation
Jaguar Health has a market cap or net worth of $5.01 million. The enterprise value is $37.69 million.
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Jaguar Health has 1.26 million shares outstanding. The number of shares has increased by 934.82% in one year.
| Current Share Class | 1.26M |
| Shares Outstanding | 1.26M |
| Shares Change (YoY) | +934.82% |
| Shares Change (QoQ) | +31.57% |
| Owned by Insiders (%) | 8.45% |
| Owned by Institutions (%) | 5.53% |
| Float | 1.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.15 |
| Forward PS | 0.33 |
| PB Ratio | 1.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 11.56.
| Current Ratio | 1.08 |
| Quick Ratio | 0.25 |
| Debt / Equity | 11.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -459.52% and return on invested capital (ROIC) is -44.79%.
| Return on Equity (ROE) | -459.52% |
| Return on Assets (ROA) | -37.48% |
| Return on Invested Capital (ROIC) | -44.79% |
| Return on Capital Employed (ROCE) | -137.78% |
| Revenue Per Employee | $235,755 |
| Profits Per Employee | -$810,816 |
| Employee Count | 49 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.05% in the last 52 weeks. The beta is 0.96, so Jaguar Health's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -96.05% |
| 50-Day Moving Average | 6.55 |
| 200-Day Moving Average | 19.99 |
| Relative Strength Index (RSI) | 32.98 |
| Average Volume (20 Days) | 110,564 |
Short Selling Information
The latest short interest is 32,263, so 2.55% of the outstanding shares have been sold short.
| Short Interest | 32,263 |
| Short Previous Month | 114,446 |
| Short % of Shares Out | 2.55% |
| Short % of Float | 3.15% |
| Short Ratio (days to cover) | 0.14 |
Income Statement
In the last 12 months, Jaguar Health had revenue of $11.55 million and -$39.73 million in losses. Loss per share was -$93.55.
| Revenue | 11.55M |
| Gross Profit | 9.51M |
| Operating Income | -32.04M |
| Pretax Income | -38.32M |
| Net Income | -39.73M |
| EBITDA | -30.16M |
| EBIT | -32.04M |
| Loss Per Share | -$93.55 |
Full Income StatementBalance Sheet
The company has $5.69 million in cash and $38.34 million in debt, giving a net cash position of -$32.65 million or -$25.81 per share.
| Cash & Cash Equivalents | 5.69M |
| Total Debt | 38.34M |
| Net Cash | -32.65M |
| Net Cash Per Share | -$25.81 |
| Equity (Book Value) | 3.32M |
| Book Value Per Share | 2.64 |
| Working Capital | 2.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.65 million and capital expenditures -$16,000, giving a free cash flow of -$29.67 million.
| Operating Cash Flow | -29.65M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -29.67M |
| FCF Per Share | -$23.46 |
Full Cash Flow StatementMargins
| Gross Margin | 82.34% |
| Operating Margin | -277.33% |
| Pretax Margin | -350.41% |
| Profit Margin | n/a |
| EBITDA Margin | -261.07% |
| EBIT Margin | -277.33% |
| FCF Margin | n/a |
Dividends & Yields
Jaguar Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -934.82% |
| Shareholder Yield | -934.82% |
| Earnings Yield | -787.36% |
| FCF Yield | -587.97% |
Analyst Forecast
The average price target for Jaguar Health is $60.00, which is 1,415.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $60.00 |
| Price Target Difference | 1,415.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 24, 2025. It was a reverse split with a ratio of 0.04:1.
| Last Split Date | Mar 24, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.04:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |